Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06602011
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-17
Brief Title:
Triple Therapy for Intermediate-advanced HCC With BDTT TALENP002
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Transcatheter Arterial Chemoembolization Combined With Lenvatinib Plus Tislelizumab for Intermediate-advanced Hepatocellular Carcinoma With Bile Duct Tumor Thrombus A Multicenter Single-arm Real-world Study
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter Single-arm Real-world Study to evaluate the efficacy and safety of Transcatheter arterial chemoembolization TACE Lenvatinib combined with Tislelizumab Triple Therapy for patients with Hepatocellular Carcinoma HCC with bile duct tumor thrombus BDTT
Detailed Description:
Surgical resection is considered to be the treatment of choice for Hepatocellular Carcinoma HCC combined with bile duct tumor thrombus BDTT but a significant proportion of patients with HCC combined with BDTT are unable to undergo surgical treatment at the time of initial diagnosis For patients with unresectable advanced HCC combined with BDTT conversion therapy is particularly important Currently there is relatively little literature related to the conversion treatment of HCC with BDTT Several studies have confirmed that the transcatheter arterial chemoembolization TACE lenvatinib combined with Tislelizumab Triple Therapy for the treatment of intermediate-advanced HCC can achieve better efficacy with an acceptable safety However there are no clinical studies or relevant literature reports on Triple Therapy for the treatment of HCC with BDTT The present study is a multicenter Single-arm Real-world Study designed to evaluate the efficacy and safety of a triple therapy for the treatment of patients with HCC with BDTT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None